Will Its HIV Lineup Save Gilead Sciences?

Gilead Sciences (NASDAQ:GILD) failed to impress investors with its latest earnings report released on Oct. 24. Not only did the company's revenues remain pretty much flat compared to the year-ago period, but the pharma giant's GAAP net income of more than $2 billion in Q3 2018 turned into a net loss this time around. This is nothing new for Gilead: The company has been struggling mightily over the past few years as its hepatitis C business is not performing nearly as well as it used to. Gilead's shares have been on a downward spiral since mid-2015. Perhaps the sole bright spot of the company's business, though, is its HIV lineup.